Carey K. Anders, MD, discusses navigating the treatment landscape of metastatic triple-negative breast cancer.
Carey K. Anders, MD, medical oncologist, medical director, Brain and Spine Metastases Program, Duke Cancer Center, Duke Health, discusses navigating the treatment landscape of metastatic triple-negative breast cancer (mTNBC).
Several factors should be considered when selecting treatment for a patient with mTNBC, Anders explains. These factors include the patient’s symptom burden, their baseline health status, and the tolerability of the therapy. Additionally, patient preference is an important factor to consider during the decision-making process, Anders adds.
Moreover, from a biological perspective, it is important understand whether the patient is PD-L1 positive or negative. Patients with PD-L1–positive disease are eligible to receive up-front chemoimmunotherapy, whereas patients with PD-L1–negative disease receive single-agent chemotherapy in the frontline setting, Anders explains.
In the second- and later-line settings, the antibody-drug conjugate sacituzumab govitecan-hziy (Trodelvy) or clinical trials may be considered, Anders concludes.